Other substances

Chlorpromazine

A postsynaptic dopamine receptor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Chlorpromazine is a phenothiazine antipsychotic drug. It blocks postsynaptic dopamine receptors in the brain (NCIt).

Chlorpromazine on DrugBank
Chlorpromazine on PubChem
Chlorpromazine on Wikipedia

Synonyms

Chlorpromazine hydrochloride

Marketed as

CHLORPROMAZINE HYDROCHLORIDE

CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine Preprint	human A549-ACE2 cells			May/06/2020
Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo Small molecule Animal model	BALB/c mice; A549 lung adenocarcinoma cells expressing ACE2; Vero E6 cells; SARS-CoV-2 strain MA15	4.32	Protected mice infected by mouse-adapded SARS-CoV-2 from clinical disease. Did not inhibit viral replication in the lungs, however. Inhibits the production of infectious viral particles in vitro and decreases viral gene RNA levels.	Aug/19/2020
Screened antipsychotic drugs inhibit SARS-CoV-2 binding with ACE2 in vitro ACE2 Biophysical assay In vitro In silico	in silico; in vitro biophysical assay; ACE2 high-expressing HEK293T cells; ACE2-HEK293T cell membrane chromatography	3.65	Bound to ACE2 and cell membranes of ACE2-expressing cells and reduced SARS-CoV-2 Spike pseudotyped virus entry ratio in vitro.	Dec/10/2020

AI-suggested references

Link	Publication date
Antimalarial Quinacrine and Chloroquine Lose Their Activity by Decreasing Cationic Amphiphilic Structure with a Slight Decrease in pH.	Nov/08/2021
Repurposing Psychotropic Agents for Viral Disorders: Beyond Covid.	Aug/10/2021
Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo	Oct/14/2020
On a knife's edge of a COVID-19 pandemic: is containment still possible?	Mar/09/2020
Computational identification of repurposed drugs against viruses causing epidemics and pandemics via drug-target network analysis.	Jul/23/2021
Observational Study of Chlorpromazine in Hospitalized Patients with COVID-19	Mar/17/2022
Repurposing chlorpromazine to treat COVID-19: The reCoVery study	Mar/02/2022
Antidepressant and Antipsychotic Drugs Reduce Viral Infection by SARS-CoV-2 and Fluoxetine Shows Antiviral Activity Against the Novel Variants in vitro	Jun/07/2021
On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2.	Aug/19/2020

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04354805	Administration of Chlorpromazine as a Treatment for COVID-19	Not yet recruiting	Phase 2\|Phase 3	Aug/01/2020	Nov/01/2020
Alternative id - Medical Interventions - Drug: Chlorpromazine Study type - Interventional Study results - No Results Available Locations - Cairo University, Cairo, Egypt Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Single (Participant)\|Primary Purpose: Treatment Enrollment - 100 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Clinical improvement
NCT04366739	Repurposing of Chlorpromazine in Covid-19 Treatment	Not yet recruiting	Phase 3	Apr/29/2020	Sep/30/2020
Alternative id - D20-P016 Interventions - Drug: CHLORPROMAZINE (CPZ)\|Combination Product: Standard of Care (SOC) Study type - Interventional Study results - No Results Available Locations - Centre Hospitalier Sainte-Anne, Paris, France Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Single (Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 40 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Time To Response (TTR)\|Objective Response Rate (ORR)\|All-cause mortality\|Duration in days required for hospital discharge\|Duration in days required for National Early Warning Score ≤ 2 maintained 24 hours\|Number of days without oxygen therapy\|Incidence of oxygen use, NIV or high flow oxygen therapy\|Duration in days of oxygen prescription, NIV or high flow oxygen therapy\|Biochemical response: rate of patients positive for SARS-CoV-2 PCR on a nasopharyngeal sample\|Biochemical response: viral load of SARS-CoV-2 on a nasopharyngeal sample\|Biochemical response: serum viral load of SARS-CoV-2\|Biochemical response: C-reactive protein (CRP)\|Biochemical response: blood test for lymphocytes (lymphopenia)\|Parenchymal involvement (chest CT)\|Define the optimal dose of CPZ and its tolerance: rates of serious adverse events\|Define the optimal dose of CPZ and its tolerance: rates of non-serious side effects\|Define the optimal dose of CPZ and its tolerance: anxiety assessment on Global Anxiety - Visual Analog Scale (GA-VAS)\|Define the optimal dose of CPZ and its tolerance: Rates of drug discontinuation\|Define the optimal dose of CPZ and its tolerance: biological anomalies\|Define the optimal dose of CPZ and its tolerance: ECG abnormalities\|Define the optimal dose of CPZ and its tolerance: plasma CPK assessment\|Define the optimal dose of CPZ and its tolerance:plasma CPZ assessment\|Define the optimal dose of CPZ and its tolerance: CPZ dose administered

Export (.csv)